Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine

被引：111

作者：

Bönöczk, P

Gulyás, B

Adam-Vizi, V

Nemes, A

Kárpáti, E

Kiss, B

Kapás, M

Szántay, C

Koncz, I

Zelles, T

Vas, A

机构：

[1] Chem Works Gedeon Richter Ltd, H-1475 Budapest 10, Hungary

[2] Karolinska Inst, Dept Neurosci, Stockholm, Sweden

[3] Semmelweis Univ, Dept Med Biochem, H-1085 Budapest, Hungary

[4] Tech Univ, Dept Organ Chem, Budapest, Hungary

[5] Hungarian Acad Sci, Inst Expt Med, Budapest, Hungary

来源：

BRAIN RESEARCH BULLETIN | 2000年 / 53卷 / 03期

关键词：

vinpocetine; cerebrovascular disorders; neuroprotection; PET studies;

D O I：

10.1016/S0361-9230(00)00354-3

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Vinpocetine (ethyl apovincaminate) discovered during the late 1960s has successfully been used in the treatment of central nervous system disorders of cerebrovascular origin for decades. The increase in the regional cerebral blood flow in response to vinpocetine administration is well established and strengthened by new diagnostical techniques (transcranial Doppler, near infrared spectroscopy, positron emission tomography). The latest in vitro studies have revealed the effect of the compound on Ca2+/calmodulin dependent cyclic guanosine monophosphate-phosphodiesterase 1, voltage-operated Ca2+ channels, glutamate receptors and voltage dependent Na+ -channels; the latest being especially relevant to the neuroprotective action of vinpocetine. The good brain penetration profile and heterogenous brain distribution pattern (mainly in the thalamus, basal ganglia and visual cortex) of labelled vinpocetin were demonstrated by positron emission tomography in primates and man. Multicentric, randomized, placebo-controlled clinical studies proved the efficacy of orally administered vinpocetin in patients with organic psychosyndrome. Recently positron emission tomography studies have proved that vinpocetine is able to redistribute regional cerebral blood flow and enhance glucose supply of brain tissue in ischemic post-stroke patients. (C) 2000 Elsevier Science Inc.

引用

页码：245 / 254

页数：10

共 111 条

[1]

386202 AT, 1988, Patent No. 386202

[2] MESOMORPHIC STILBAZOLE COMPLEXES OF SILVER OCTYL SULFATE - CRYSTAL AND MOLECULAR-STRUCTURE OF BIS[4-(4-METHOXYSTYRYL)PYRIDINATO]SILVER(I) OCTYL SULFATE HEMIHYDRATE [J].